Mahmood Alam, MD
Pulmonary Disease · Whitesburg, KYNPI 1083669741
Payments from drug & device makers
Across 404 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$929
- Sanofi$320
- Boehringer Ingelheim$301
- AstraZeneca$278
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,56697%
- Education$2123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 86 | $1,504 |
| GSK | 114 | $1,471 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $929 |
| Sanofi | 16 | $320 |
| Boehringer Ingelheim | 15 | $301 |
| AstraZeneca | 15 | $278 |
| Regeneron Healthcare Solutions, Inc. | 14 | $233 |
| Mylan Specialty L.p. | 11 | $206 |
| Shire North American Group Inc | 20 | $205 |
| Mallinckrodt Hospital Products Inc. | 5 | $189 |
| Viatris Specialty LLC | 8 | $167 |
| Insmed, Inc. | 7 | $156 |
| Amgen | 6 | $137 |
| Sunovion Pharmaceuticals Inc. | 10 | $118 |
| Genentech USA, Inc. | 1 | $100 |
| Verona Pharma, Inc. | 5 | $82 |
| Philips North America LLC | 4 | $75 |
| Cleerly, Inc. | 1 | $55 |
| Vifor Pharma, Inc. | 3 | $49 |
| Baxter Healthcare | 2 | $33 |
| Bio Products Laboratory USA, Inc. | 1 | $25 |
| Pulmonx Corporation | 1 | $22 |
| Electromed, Inc. | 2 | $22 |
| ADMA Biomanufacturing LLC | 1 | $18 |
| Insulet Corporation | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| United Therapeutics Corporation | 1 | $14 |
| Circassia Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
How this compares
$6,778 in reported general payments places this provider in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 173 | $2,090,904 |
| GlassiaAlpha-1-Proteinase Inhibitor | 112 | $1,595,889 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 99 | $263,024 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 38 | $251,561 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $183,829 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 79 | $177,115 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $132,419 |
| Dupixent PenDupilumab | 20 | $94,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $89,441 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $59,112 |
| XolairOmalizumab | 11 | $58,728 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $34,420 |
| EliquisApixaban | 46 | $29,148 |
| SymbicortBudesonide/Formoterol Fumarate | 95 | $25,987 |
| Spiriva RespimatTiotropium Bromide | 34 | $24,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C, Gamunex-C | $1,504 | $2,268,019252 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia, Gammagard Liquid, Cuvitru | $929 | $2,110,474249 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $1,471 | $122,045206 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $278 | $60,407144 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $301 | $40,12962 claims |
| PfizerEliquis | $11 | $29,14846 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $25 | $19,27111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Whitesburg
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Steven KoenigMorehead$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.